Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Karl Kieburtz, MD

Neurology Rochester, NY Male

NPI: 1619081122

Total Payments

$405,017

2024 Payments

$9,169

Companies

Transactions

Payment Breakdown by Category

Consulting$378,550 (93.5%)

Other$16,075 (4.0%)

Travel$9,928 (2.5%)

Food & Beverage$464.26 (0.1%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Consulting Fee	$378,550	61	93.5%
Honoraria	$10,675	2	2.6%
Travel and Lodging	$9,928	13	2.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$5,400	1	1.3%
Food and Beverage	$464.26	11	0.1%

Top Paying Companies

Company	Total	Records	Latest Year
Acorda Therapeutics, Inc	$159,000	22	$0 (2018)
Roche Products Limited	$57,650	11	$0 (2022)
Teva Pharmaceuticals USA, Inc.	$41,409	10	$0 (2018)
Kyowa Kirin, Inc.	$35,000	4	$0 (2022)
Neurocrine Biosciences, Inc.	$19,500	6	$0 (2018)
H. Lundbeck A S	$17,810	5	$0 (2024)
UCB Biosciences Inc.	$16,614	12	$0 (2018)
Janssen Research & Development, LLC	$13,400	2	$0 (2024)
SANOFI US SERVICES INC.	$11,421	5	$0 (2017)
Millennium Pharmaceuticals, Inc.	$11,079	3	$0 (2017)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$9,169	3	Janssen Research & Development, LLC ($7,400)
2023	$10,000	1	Eisai Inc. ($10,000)
2022	$75,191	13	Kyowa Kirin, Inc. ($35,000)
2021	$7,700	3	Grifols, S.A. ($7,700)
2020	$6,000	1	Janssen Research & Development, LLC ($6,000)
2019	$2,400	1	UCB SA ($2,400)
2018	$129,221	25	Acorda Therapeutics, Inc ($67,500)
2017	$165,337	41	Acorda Therapeutics, Inc ($91,500)

All Payment Transactions

88 individual payment records from CMS Open Payments — Page 1 of 4

Date	Company	Product	Nature	Form	Amount	Type
08/23/2024	Sage Therapeutics, Inc.	—	Consulting Fee	Cash or cash equivalent	$1,000.00	General
06/14/2024	H. Lundbeck A S	—	Honoraria	Cash or cash equivalent	$769.00	General
04/01/2024	Janssen Research & Development, LLC	—	Consulting Fee	Cash or cash equivalent	$7,400.00	General
08/02/2023	Eisai Inc.	Leqembi (Drug)	Consulting Fee	Cash or cash equivalent	$10,000.00	General
Category: Neurology
11/29/2022	H. Lundbeck A S	BRINTELLIX (Drug)	Honoraria	Cash or cash equivalent	$9,906.45	General
Category: PSYCHIATRY
11/29/2022	H. Lundbeck A S	BRINTELLIX (Drug)	Travel and Lodging	Cash or cash equivalent	$6,783.61	General
Category: PSYCHIATRY
11/29/2022	H. Lundbeck A S	BRINTELLIX (Drug)	Travel and Lodging	Cash or cash equivalent	$256.58	General
Category: PSYCHIATRY
11/29/2022	H. Lundbeck A S	BRINTELLIX (Drug)	Food and Beverage	Cash or cash equivalent	$94.11	General
Category: PSYCHIATRY
11/21/2022	Genentech, Inc.	Non-Covered Product	Consulting Fee	Cash or cash equivalent	$1,000.00	General
10/12/2022	Roche Products Limited	—	Consulting Fee	Cash or cash equivalent	$5,750.00	General
07/13/2022	Roche Products Limited	—	Consulting Fee	Cash or cash equivalent	$5,250.00	General
06/16/2022	Roche Products Limited	—	Consulting Fee	Cash or cash equivalent	$6,150.00	General
06/07/2022	Kyowa Kirin, Inc.	—	Consulting Fee	Cash or cash equivalent	$8,750.00	General
05/04/2022	Roche Products Limited	—	Consulting Fee	Cash or cash equivalent	$5,000.00	General
05/03/2022	Kyowa Kirin, Inc.	—	Consulting Fee	Cash or cash equivalent	$8,750.00	General
03/31/2022	Kyowa Kirin, Inc.	—	Consulting Fee	Cash or cash equivalent	$8,750.00	General
03/03/2022	Kyowa Kirin, Inc.	—	Consulting Fee	Cash or cash equivalent	$8,750.00	General
04/29/2021	Grifols, S.A.	—	Consulting Fee	Cash or cash equivalent	$2,100.00	General
02/26/2021	Grifols, S.A.	—	Consulting Fee	Cash or cash equivalent	$2,100.00	General
01/19/2021	Grifols, S.A.	—	Consulting Fee	Cash or cash equivalent	$3,500.00	General
11/04/2020	Janssen Research & Development, LLC	—	Consulting Fee	Cash or cash equivalent	$6,000.00	General
05/03/2019	UCB SA	—	Consulting Fee	Cash or cash equivalent	$2,400.00	General
11/09/2018	UCB Biosciences Inc.	—	Consulting Fee	Cash or cash equivalent	$3,000.00	General
09/28/2018	UCB Biosciences Inc.	—	Consulting Fee	Cash or cash equivalent	$7,200.00	General
09/28/2018	UCB Biosciences Inc.	—	Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	Cash or cash equivalent	$5,400.00	General

1 2 3 4 »

About Dr. Karl Kieburtz, MD

Dr. Karl Kieburtz, MD is a Neurology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619081122.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Karl Kieburtz, MD has received a total of $405,017 in payments from pharmaceutical and medical device companies, with $9,169 received in 2024. These payments were reported across 88 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($378,550).

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Neurology
Location Rochester, NY
Active Since 08/19/2006
Last Updated 07/18/2012
Taxonomy Code 2084N0400X
Entity Type Individual
NPI Number 1619081122

Products in Payments

Non-Covered Product (Drug) $35,500
BRINTELLIX (Drug) $17,041
PRIDOPIDINE (Drug) $16,346
Leqembi (Drug) $10,000
LEMTRADA (Drug) $6,000
NO PRODUCT DISCUSSED (Drug) $5,456
LAQUINIMOD (Drug) $4,200
Non-Covered Product $1,000

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.